Morningstar

Qiagen NV QIA

Morningstar Rating
Unlock
Stock XETR Rating as of
€41.02 +0.89 (2.22%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Qiagen Still Pushing for Higher Growth Than Its End Markets

Julie Utterback

Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, which should remain in high demand even after the pandemic, albeit probably at a reset rate following that unique event. Qiagen's roots are in products that help scientists prepare biological samples for various experiments, and sample preparation products account for nearly 35% of sales. Qiagen remains a key leader in this niche, and we expect Qiagen to continue to invest to maintain or improve in that business in the long run.

Read Full Report

Price vs Fair Value

View History
QIA is trading at a 57% premium.
Price
€41.01
Fair Value
€14.00
Uncertainty
Medium
1-Star Price
€79.90
5-Star Price
€83.60
Economic Moat
Ddvl
Capital Allocation
Fprynhkd

Bulls Say, Bears Say

Bulls

Qiagen’s long-term growth prospects in the life science and diagnostic markets will not dissolve after the pandemic.

Bears

Competitive threats in Qiagen's chosen fields, particularly diagnostics, may always remain high given the risk of disruptive innovation from new and established organizations.

Show More

Trading Information

Previous Close Price
€40.13
Day Range
€40.45–41.20
52-Week Range
€33.75–43.49
Bid/Ask
€0.00 / €0.00
Market Cap
€9.12 Bil
Volume/Avg
436,404 / 434,397

Key Statistics

Price/Earnings (Normalized)
21.38
Price/Sales
5.03
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
3.00%

Company Profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Core
Total Number of Employees
5,900
Website
https://www.qiagen.com

Competitors

Valuation

View More
Metric
QIA
ILMN
TMO
Price/Earnings (Normalized)
 21.38141.4328.13
Price/Book Value
 2.8714.434.95
Price/Sales
 5.034.665.59
Price/Cash Flow
 17.4953.5727.55
Price/Earnings
QIA
ILMN
TMO

Financial Strength

Metric
QIA
ILMN
TMO
Quick Ratio
 1.200.741.24
Current Ratio
 1.771.111.72
Interest Coverage
 1.50−39.584.91
Quick Ratio
QIA
ILMN
TMO

Profitability

Metric
QIA
ILMN
TMO
Return on Assets (Normalized)
 7.87%1.51%8.68%
Return on Equity (Normalized)
 12.93%2.86%18.42%
Return on Invested Capital (Normalized)
 8.64%2.18%10.79%
Return on Assets
QIA
ILMN
TMO

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
RsqcpqfjfLjzj$234.7 Bil
 Danaher Corp
DHR
GgmspwbphJmkkn$198.9 Bil
 IQVIA Holdings Inc
IQV
HzgblgfgCnvcbbn$42.8 Bil
 Agilent Technologies Inc
A
SnzsppjkwQqt$42.5 Bil
 IDEXX Laboratories Inc
IDXX
SfrvbczmgZyt$42.1 Bil
 Mettler-Toledo International Inc
MTD
FjqjdmcbrbFkssyg$31.4 Bil
 Icon PLC
ICLR
TxgmfphlrJqlsxqk$23.7 Bil
 Waters Corp
WAT
WgjqvcgtzMcr$21.2 Bil
 Illumina Inc
ILMN
RzywwcbYgzxzq$20.7 Bil
 Labcorp Holdings Inc
LH
NmgljxchzKfgmpt$18.6 Bil

Sponsor Center